Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.

Literature DB >> 1328538

Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.

H A Ring¹, M R Trimble, D C Costa, M S George, P Verhoeff, P J Ell.

Abstract

Vigabatrin is a specific gamma-aminobutyric acid transaminase inhibitor. The clinical use of this drug in the treatment of epilepsy has been sporadically linked to the development of psychosis. Using 123I-IBZM, a specific dopamine D2 receptor ligand and single photon emission tomography (SPET), one month of treatment with vigabatrin was associated with a decrease in specific binding of 123I-IBZM to D2 receptors in the left hemisphere basal ganglia. This change may provide one explanation for the development of psychosis in vulnerable patients.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1328538 PMCID： PMC1015097 DOI： 10.1136/jnnp.55.9.758

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

19 in total

1. Effects of chronic cocaine abuse on postsynaptic dopamine receptors.

Authors: N D Volkow; J S Fowler; A P Wolf; D Schlyer; C Y Shiue; R Alpert; S L Dewey; J Logan; B Bendriem; D Christman
Journal: Am J Psychiatry Date: 1990-06 Impact factor: 18.112

2. Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity.

Authors: A A Grace; B S Bunney
Journal: Brain Res Date: 1985-05-06 Impact factor: 3.252

3. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.

Authors: H F Kung; S Pan; M P Kung; J Billings; R Kasliwal; J Reilley; A Alavi
Journal: J Nucl Med Date: 1989-01 Impact factor: 10.057

4. Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist.

Authors: W Singhaniyom; Y F Tsai; T Brücke; C A McLellan; R M Cohen; H F Kung; C C Chiueh
Journal: Brain Res Date: 1988-06-21 Impact factor: 3.252

Review 1. Infantile spasms.

Authors: R E Appleton
Journal: Arch Dis Child Date: 1993-11 Impact factor: 3.791

Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.

1. Effects of chronic cocaine abuse on postsynaptic dopamine receptors.

2. Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity.

3. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.

4. Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist.

5. Neurochemical interactions of cocaine with dopaminergic systems.

6. Statistical methods for assessing agreement between two methods of clinical measurement.

7. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain.

8. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.

9. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.

10. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.

Review 1. Infantile spasms.

Review 2. Place of newer antiepileptic drugs in the treatment of epilepsy.

3. Eye-blink rate predicts individual differences in pseudoneglect.

Review 4. Behavioural effects of the new anticonvulsants.